Published in Cell on September 04, 2014
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Organoid models of human and mouse ductal pancreatic cancer. Cell (2014) 2.99
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol (2015) 2.09
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Rep (2015) 1.43
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature (2017) 1.42
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature (2017) 1.38
Organoids as an in vitro model of human development and disease. Nat Cell Biol (2016) 1.27
Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer (2015) 1.24
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med (2017) 1.21
Role of non-coding sequence variants in cancer. Nat Rev Genet (2016) 1.10
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc (2016) 0.99
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget (2015) 0.95
Tissue-engineered models of human tumors for cancer research. Expert Opin Drug Discov (2015) 0.95
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget (2015) 0.93
Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade. Cell Rep (2015) 0.92
A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med (2016) 0.91
Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. PLoS One (2015) 0.90
The biology of circulating tumor cells. Oncogene (2015) 0.90
A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res (2016) 0.87
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell (2016) 0.87
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov (2017) 0.87
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87
Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A (2015) 0.85
Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J (2015) 0.85
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol (2016) 0.84
Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis (2015) 0.84
Orthotopic patient-derived xenografts of paediatric solid tumours. Nature (2017) 0.83
Preclinical models of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.83
Development and application of human adult stem or progenitor cell organoids. Nat Rev Nephrol (2015) 0.82
Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. Cancer Res (2015) 0.82
Genomic predictors for treatment of late stage prostate cancer. Asian J Androl (2016) 0.81
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials (2015) 0.81
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl (2016) 0.81
Functional/activity network (FAN) analysis of gene-phenotype connectivity liaised by grape polyphenol resveratrol. Oncotarget (2016) 0.81
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell (2017) 0.81
Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit Rev Clin Lab Sci (2015) 0.80
Cellular O-Glycome Reporter/Amplification to explore O-glycans of living cells. Nat Methods (2015) 0.80
Short term ex-vivo expansion of circulating head and neck tumour cells. Oncotarget (2016) 0.80
Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine (2016) 0.79
Modeling pancreatic cancer with organoids. Trends Cancer (2016) 0.79
Three-dimensional Organotypic Culture Models of Human Hepatocellular Carcinoma. Sci Rep (2016) 0.79
Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. Bioinformatics (2015) 0.79
Cell lines from circulating tumor cells. Oncoscience (2015) 0.79
SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Rep (2015) 0.79
Impact of label-free technologies in head and neck cancer circulating tumour cells. Oncotarget (2016) 0.79
Organoid development in cancer genome discovery. Curr Opin Genet Dev (2015) 0.79
Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut (2016) 0.79
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife (2016) 0.79
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv (2016) 0.78
Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines. Cell Death Dis (2015) 0.78
Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene (2016) 0.78
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Curr Colorectal Cancer Rep (2016) 0.77
Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat Med (2016) 0.77
Stem cells in genetically-engineered mouse models of prostate cancer. Endocr Relat Cancer (2015) 0.77
Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open (2016) 0.77
Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. Sci Rep (2017) 0.77
Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Sci Rep (2016) 0.77
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience (2015) 0.77
Notch signaling in prostate cancer: refining a therapeutic opportunity. Histol Histopathol (2015) 0.77
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS One (2016) 0.77
Cellular plasticity: 1712 to the present day. Curr Opin Cell Biol (2016) 0.77
Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. J Biomol Screen (2016) 0.77
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
Revisiting the role of Wnt/β-catenin signaling in prostate cancer. Mol Cell Endocrinol (2017) 0.77
Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology. J Cancer Res Clin Oncol (2015) 0.76
Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest (2016) 0.76
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies. Indian J Surg Oncol (2016) 0.76
Innovation: organoids-a better model for prostate cancer. Nat Rev Urol (2014) 0.76
Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. Transl Androl Urol (2015) 0.76
p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer. Oncogene (2016) 0.75
Cell biology: Prostate cancer in 3D. Nat Methods (2014) 0.75
A Versatile Microarray Platform for Capturing Rare Cells. Sci Rep (2015) 0.75
Prostate cancer organoids: a potential new tool for testing drug sensitivity. Expert Rev Anticancer Ther (2015) 0.75
Bioluminescence-mediated longitudinal monitoring of adipose-derived stem cells in a large mammal ex vivo organ culture. Sci Rep (2015) 0.75
Pathomimetic cancer avatars for live-cell imaging of protease activity. Biochimie (2015) 0.75
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel) (2017) 0.75
Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back. Int J Mol Sci (2016) 0.75
Drug Discovery via Human-Derived Stem Cell Organoids. Front Pharmacol (2016) 0.75
Emerging concepts in liquid biopsies. BMC Med (2017) 0.75
When Prostate Cancer Circulates in the Bloodstream. Diagnostics (Basel) (2015) 0.75
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res (2016) 0.75
Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. Front Oncol (2017) 0.75
Fluidic Logic Used in a Systems Approach to Enable Integrated Single-Cell Functional Analysis. Front Bioeng Biotechnol (2016) 0.75
Value of Organoids from Comparative Epithelia Models. Yale J Biol Med (2015) 0.75
The many ways to make a luminal cell and a prostate cancer cell. Endocr Relat Cancer (2015) 0.75
Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids. Integr Biol (Camb) (2016) 0.75
Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Front Cell Dev Biol (2016) 0.75
Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer. Biomed Opt Express (2016) 0.75
Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing. Nat Commun (2017) 0.75
Major milestones in translational oncology. BMC Med (2016) 0.75
Genome engineering of stem cell organoids for disease modeling. Protein Cell (2017) 0.75
The cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids. Cancer Sci (2017) 0.75
Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget (2016) 0.75
Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer. Oncotarget (2017) 0.75
Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion. PLoS One (2017) 0.75
Model organoids provide new research opportunities for ductal pancreatic cancer. Mol Cell Oncol (2015) 0.75
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2012) 25.21
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature (2009) 19.18
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol (2011) 10.63
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell (2010) 7.25
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature (2013) 4.94
A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim (1999) 4.93
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol (2011) 4.59
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
VCaP, a cell-based model system of human prostate cancer. In Vivo (2001) 3.36
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J (2013) 2.24
Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res (1997) 2.02
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res (2013) 1.42
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol (2013) 1.22
Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J (2013) 1.19
Prostate carcinoma: tissue culture cell lines. Natl Cancer Inst Monogr (1978) 1.04
Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol (2004) 1.04
Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol (2013) 0.90
ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma. Hum Pathol (2013) 0.81
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell (2014) 3.05
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell (2014) 1.73
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Rep (2015) 1.43
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell (2016) 0.87
Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol (2009) 0.87
Organoid development in cancer genome discovery. Curr Opin Genet Dev (2015) 0.79
Stromal Hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer. Dis Model Mech (2016) 0.75